[ad_1]
Jazz Pharmaceuticals (NASDAQ: JAZZ) 2.9% falls in after-hours trading after reporting results of a late-stage trial of liposome Vyxeos for injections in two kinds of blood cancer.
The study 309 patients between 60 and 70 years of age with newly diagnosed therapy-related acute myeloid leukemia or with myelodysplasia-related changes, a rapidly progressing and life-threatening blood cancer.
While the study puts its findings Primary endpoint of improvement in overall survival, fatal treatment-emergent CNS hemorrhage in the setting of progressive disease in patients in the Vyxeos arm and 0.7% of patients in the control arm
Six percent of patients in both The study of Vyxeos liposome demonstrated compared to survival of the disease in vitro.
with the standard care cytarabine and daunorubicin (7 + 3) – median OS of 9.6 months for the Vyxeos group vs. 5.9 months for the 7 + 3 treatment group.
Jazz said Vyxeos was significantly more successful than 7 + 3 with a complete response of 38%. 26%.
Vyxeos was approved by the US Food and Drug Administration in August 2017, and is the first FDA -produced FDA-approved for adults with newly-diagnosed AML-AML or AML-MRC.
Source: Press Release
[ad_2]
Source link
